Literature DB >> 1373384

Sero epidemiological characteristics of hepatitis C encountered in general practice in Belgium.

R Vranckx1, D Walckiers, A Stroobant, G Thiers.   

Abstract

A study carried out between 1982 and 1984 established by exclusion diagnosis that 35% of viral hepatitis cases registered in Belgium were due to non A, non B (NANB) viruses. Recently, a new anti-hepatitis C virus (HCV) detection test was used to analyse the sera of patients in whom NANB hepatitis was diagnosed in that study. Using this new serological test for HCV, 29% of the NANB group was found to be positive for anti-HCV. In the 1982-84 study on viral hepatitis diagnosed by general practitioners, the number of clinically recognized infections was estimated at 14,700 (+/- 2,170; confidence interval at 95%) per year. By combining these data and the results of the present study, the following estimates could be calculated: HAV (7,129 +/- 1,054/year), HBV (2,426 +/- 358/year), HCV (1,470 +/- 216/year) and non-identified hepatitis viruses (3,675 +/- 543/year).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373384     DOI: 10.1007/bf01971275

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  11 in total

1.  Hepatitis C in institutionalized children.

Authors:  R Vranckx; P Van Damme
Journal:  N Engl J Med       Date:  1990-07-05       Impact factor: 91.245

2.  Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome.

Authors:  Q L Choo; G Kuo; A J Weiner; L R Overby; D W Bradley; M Houghton
Journal:  Science       Date:  1989-04-21       Impact factor: 47.728

3.  Antibodies to hepatitis C virus in French blood donors.

Authors:  C Janot; A M Couroucé; M Maniez
Journal:  Lancet       Date:  1989-09-30       Impact factor: 79.321

4.  Antibodies to hepatitis C virus in Italian blood donors.

Authors:  G Sirchia; A Bellobuono; A Giovanetti; M Marconi
Journal:  Lancet       Date:  1989-09-30       Impact factor: 79.321

5.  Antibody to hepatitis C virus in German blood donors.

Authors:  P Kühnl; S Seidl; W Stangel; J Beyer; W Sibrowski; J Flik
Journal:  Lancet       Date:  1989-08-05       Impact factor: 79.321

Review 6.  The elusive hepatitis C virus.

Authors:  A J Zuckerman
Journal:  BMJ       Date:  1989-10-07

7.  [A morbidity surveillance program in Belgium. A registration system for reporting physicians].

Authors:  J M Lamotte; R Cornélis; A Stroobant; G Thiers; V Van Casteren; D Walckiers
Journal:  Rev Med Liege       Date:  1986-04-15

8.  Anti-hepatitis C antibodies and non-A, non-B post-transfusion hepatitis in The Netherlands.

Authors:  C L van der Poel; H W Reesink; P N Lelie; A Leentvaar-Kuypers; Q L Choo; G Kuo; M Houghton
Journal:  Lancet       Date:  1989-08-05       Impact factor: 79.321

9.  Hepatitis C virus antibodies among risk groups in Spain.

Authors:  J I Esteban; R Esteban; L Viladomiu; J C López-Talavera; A González; J M Hernández; M Roget; V Vargas; J Genescà; M Buti
Journal:  Lancet       Date:  1989-08-05       Impact factor: 79.321

10.  [Various sero-epidemiological characteristics of viral hepatitis in general medicine: results of a pilot survey performed in Belgium].

Authors:  D Walckiers; R Vranckx; A Stroobant; G Thiers
Journal:  Rev Epidemiol Sante Publique       Date:  1988       Impact factor: 1.019

View more
  1 in total

1.  Prevalence of hepatitis A, B and C in the Flemish population.

Authors:  M Beutels; P Van Damme; W Aelvoet; J Desmyter; F Dondeyne; C Goilav; R Mak; L Muylle; D Pierard; A Stroobant; F Van Loock; P Waumans; R Vranckx
Journal:  Eur J Epidemiol       Date:  1997-04       Impact factor: 8.082

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.